

## HEDIS® measure spotlight: **Osteoporosis Management In Women Who Had a Fracture (OMW)**

To be measure compliant, have your **female Medicare patients between the ages of 67 and 85 complete a bone marrow density (BMD) test within six months of sustaining a fracture.**

### **Why it matters:**

Osteoporotic fractures are associated with pain, disability, loss of independence, decreased quality of life and increased mortality. With appropriate screening and treatment, you can help reduce the risk of future osteoporosis-related fractures for your patients, our members.

### **Helping your patients manage their osteoporosis post-fracture.**

1. Evaluate women ages 67 to 85 annually for risk factors that would increase the risk of osteoporosis, such as medication use.
2. Develop a standing order for a BMD test to be completed within six months for women who sustained a fracture.
3. Ensure women ages 67 to 85 are being treated in a timely manner for osteoporosis.
4. Educate patients on managing osteoporosis – osteoporosis screening is a preventive service and is covered at 100% for our Medicare members.
5. Set up a process to help identify patients with fractures and follow-up with the patients to schedule an appointment.



### **The OMW measure**

OMW assesses women 67–85 years of age who suffered a fracture and who had either a bone mineral density test or a prescription for a drug to treat osteoporosis in the six months after the fracture.

To mitigate the risk of future fractures, the [US Preventive Services Task Force](#) recommends patients receive osteoporosis screening and treatment after their first fracture.

**Coding recommendations:** Ensure proper documentation of the fracture by using complete and accurate diagnosis codes

Osteoporosis testing & treatment	CPT	HCPCS	ICD-10 PCS	SNOMED
Bone mineral density (BMD) tests	76977, 77078, 77080, 77081, 77085, 77086		BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1	22059005, 312681000, 285342005, 391057001, 391058006, 391059003, 391060008, 391061007, 391062000, 391063005, 391064004, 391065003, 391066002, 391069009, 391070005, 391071009, 391072002, 391073007, 391074001, 391076004, 391078003, 391079006, 391080009, 391081008, 391082001, 440083004, 440099005, 44010000, 449781000, 707218004, 4211000179102
Osteoporosis medication therapy		J0897, J1740, J3110, J3111, J3489		
Long-acting osteoporosis medications		J0897, J1740, J3489		

### Osteoporosis medications

Medication class	Medication		
Bisphosphonates	<ul style="list-style-type: none"> <li>Alendronate</li> <li>Alendronate-cholecalciferol</li> </ul>	<ul style="list-style-type: none"> <li>Ibandronate</li> <li>Risedronate</li> </ul>	<ul style="list-style-type: none"> <li>Zoledronic acid</li> </ul>
Other agents	<ul style="list-style-type: none"> <li>Abaloparatide</li> <li>Denosumab</li> </ul>	<ul style="list-style-type: none"> <li>Raloxifene</li> <li>Romosozumab</li> </ul>	<ul style="list-style-type: none"> <li>Teriparatide</li> </ul>